Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $44.00 | Buy | BTIG Research |
| 2/4/2025 | $20.00 | Outperform | Wolfe Research |
| 10/11/2024 | $49.00 | Buy | Stifel |
| 10/7/2024 | $45.00 | Buy | H.C. Wainwright |
| 9/17/2024 | $44.00 | Outperform | Leerink Partners |
| 9/16/2024 | Buy | TD Cowen | |
| 9/13/2024 | $40.00 | Buy | Jefferies |
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update. "We are very pleased to have initiated our EVERLAST-A study, and we expect nearl
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in September MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the U.S. FDA cleared its investigational new drug (IND) application for its Phase 2a trial of ORKA-001 (the Company's long-acting anti-IL-23p19 antibody) in moderate-
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operations, development strategy, and quality. She has played a pivotal role in progressing Oruka's programs from preclinical stages into clinical trials with speed and precision. "I've had the privilege
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00
Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00
Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00
424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)